AG 284

Drug Profile

AG 284

Alternative Names: AG-284

Latest Information Update: 14 Aug 2007

Price : $50

At a glance

  • Originator Corixa Corporation
  • Class
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 26 Aug 2003 AG 284 is still available for licensing (http://www.corixa.com)
  • 26 Aug 2003 Suspended - Phase-II for Multiple sclerosis in USA (IV)
  • 30 Jul 2002 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top